Overview

Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray

Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Part 1, the pharmacokinetic (PK) phase, will expand upon the pilot study conducted at Naval Medical Research Laboratory (NAMRL) and has the goal of determining bioavailability and time to Cmax in a larger representative sample. Part 2, the efficacy phase, is to determine the efficacy of the aqueous spray solution via exposure to a nausea-inducing stimulus.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Repurposed Therapeutics, Inc.
Treatments:
Butylscopolammonium Bromide
Scopolamine
Scopolamine Hydrobromide